Sentences with phrase «efficacy of other products»

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Whereas other baby washes often either lack scent or have a faint scent, there is no doubt about the efficacy and pleasantries of the lavender aroma produced by washing with this product from Little Twig.

Given the emerging industrial markets for commercial baby food as well as other food products, combined with scientific evidence of the efficacy of fruits and vegetables, it makes sense that baby food manufacturers would assertively advertise their products.

In 1995, Brazilian pharmaceutical companies were legally required to document pharmacological efficacy and safety as well as the predictive toxicology of phytoremedies just as for as any other pharmaceutical product.

Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes.

Stress resistance has not been assessed however and so the biological relevance of this finding is currently unknown.32 Several IER trials (75 - 85 % ER on restricted days) in overweight / obese populations have reported reductions in various markers of oxidative stress 37, 41, which in one study was accompanied by a complementary increase in the anti-oxidant uric acid.37 In a direct comparison of IER (75 % ER for two days / week) and CER, both ER strategies displayed equal efficacy in reducing levels of fast - acting advanced oxidation protein products (AOPP) after six months, which displayed a tendency to occur earlier (i.e. at three months) in the IER group.41 Levels of slow - acting (i.e. long term) AOPP tended to decrease in the IER group and increase in the CER group which the authors proposed may have resulted from IER - induced activation of autophagy, a key homeostatic cellular process in which dysfunctional or unnecessary cellular proteins are degraded and recycled.41 On the other hand, a follow - up study using similar IER / CER protocols demonstrated comparable reductions in AOPP in both groups after three months.48 Summary and Future Research Directions

No other product rivals the efficacy of Beta - 1, 3D Glucan.

This is a whole other blog entry on its way, but here are some key differences: 1) More heightened emphasis on cleansing the skin - a pillar for healthy skin 2) Extraordinary emphasis on hydration 3) Hyper - targeted serums that focus on very a la carte skincare needs 4) Nourishing the skin versus stripping it dry 5) Tons and tons of products layered on top of each other for maximum penetration and efficacy

While much of the work just described tended to focus on specific behaviors or routines drawn out of the process - product literature, other efforts tended to focus on the efficacy of larger constructs that might become the basis for teacher training.

Planet - Friendly Playtime While pet waste disposal may represent a key area for «green» product development, the combination of earth - friendliness and efficacy has become important in a variety of other pet care categories.

Kiefer said that veterinarians should consider the following before working with companies that offer stem cells: what data they have provided demonstrating the efficacy and safety of their product, whether they rely on publications by other companies or groups and whether their product is an equivalent product.

PetSmart Charities does not recommend, endorse or make any warranties or representations of any kind with regard to the accuracy, completeness, timeliness, quality, efficacy or non-infringement of any of the Materials, including any programs, services, content, products or other information provided on the Sites or by the companies or organizations linked or referred to in the Sites.

A recent independent study was done to evaluate the effectiveness of Advantage (as well as two other popular flea control products) and showed absolutely no change in efficacy compared to when the products were first introduced almost 30 years ago.

Some cases respond well to these products, and others less well: there's debate in the world of science about their efficacy.

Simparica continues to perform well, even on the last day of the month, whereas some of the other flea and tick products drop in efficacy at the end of their treatment period.»

There have been suggestions that CPV - 2c presents challenges in terms of virulence, diagnostic testing, or vaccine efficacy — but so far, studies have shown that current vaccine products as well as diagnostic tests function similarly with CPV - 2c as with the other variants.

The fact remains that caring for a pet's eyes is, indeed, an important part of tending to their overall health and well - being and, like so many other pet care products — especially those that enhance a pet's health — efficacy, quality «ingredients» and presentation are key.

What's your opinion regarding the efficacy of products such as dog chew toys, dental rinses or other dog treats in regard to dog dental care?

IVOMEC Sheep Drench, which is formulated specifically for sheep, provides a broader spectrum of efficacy than any other sheep parasite control products.

IVOMEC Drench is a liquid dewormer containing 0.08 % Ivermectin, formulated specifically for sheep to provide a broader spectrum of efficacy than other sheep parasite control product.

Hansen 2005 concluded that, at least for climate forcing agents over the historical period, Fs was a good measure of the effective forcing (the product of a forcing, however defined, and the efficacy taken relative thereto), notwithstanding that some forcings had different spatial distributions from others.

Business Manager — Duties & Responsibilities Recruit, train, and direct customer service, sales, and administrative personnel ensuring profitable operations Study internal literature to become an expert on products and services Encourage high customer retention by maintaining friendly, supportive contact with existing clients Build and strengthen relationships with key clients, industry figures, and community leaders Maintain comprehensive records detailing pricings, sales, activities reports, and other pertinent data Negotiate contracts and agreements with vendors, distributors, and partners Support human resources department through benefit administration and performance evaluations Set and strictly adhere to company budgets and project timelines Direct special projects from conception to marketplace rollout Analyze and streamline organization structure, workflow, team metrics, and client database Implement training and development programs to reinforce branding and develop team skillsets Design and execute employee recognition program to boost morale and individual efficacy Create an atmosphere of respect, professionalism, and dedication to company goals Represent company brand with poise, integrity, and positivity Consistently promoted and awarded for excellence in management, sales, and customer service

Compliance Officer — Duties & Responsibilities Responsible for identification and investigation of suspicious financial transactions Examine financial records, customer activity, and recommend appropriate remedial measures Maintain comprehensive records detailing ongoing investigations, activity reports, and other pertinent data Coordinate investigations and situation reports with legal department and applicable regulatory authorities Develop proficiencies in industry specific financial monitoring software programs Perform public figure, employee, Advice of Drawing, Dreyfuss and International Cash Letter investigations Design and implement employee training and development materials to enhance team efficacy Serve on Oversight Committee to assist in strategic planning and best practice development Train and oversee teller team and bank support staff ensuring professional operations Study internal literature to become an expert on products and services Craft effective presentations and proposals regarding compliance best practices and client investigations Recruit, train, and direct staff ensuring they understand the brand and adhere to company policies and procedures Strictly adhere to budgets and schedules Represent company brand with poise, integrity, and positivity